المؤلفون: de Velasco, Guillermo¹ Gdvelasco.gdv@gmail.com, Alonso-Gordoa, Teresa², Rodríguez-Vida, Alejo³, Anguera, Georgia⁴, Campayo, Marc⁵, Pinto, Álvaro⁶, Martínez Ortega, Esther⁷, Gallardo, Enrique⁸, Fernández Núñez, Natalia⁹, García-Carbonero, Iciar¹⁰, Reig, Oscar¹¹, Méndez-Vidal, María José¹², Fernández-Calvo, Ovidio¹³, Cassinello, Natalia Vidal¹⁴, Torregrosa, Dolores¹⁵, López-Martín, Ana¹⁶, Rosero, Adriana¹⁷, Valiente, Patricia G.¹⁸, Garcías de España, Carmen¹⁹, Climent, Miguel A.²⁰

المصدر: Clinical Genitourinary Cancer. Jun2023, Vol. 21 Issue 3, pe166-e174. 9p.

مصطلحات موضوعية: *RENAL cell carcinoma, *SUNITINIB, *TREATMENT effectiveness, *CANCER immunotherapy, *NEPHRECTOMY

مستخلص: Sunitinib, a tyrosine kinase inhibitor, has been central for the treatment of metastatic renal cell carcinoma until the recent development of immunotherapy. This study analyzed the characteristics of patients with complete response to sunitinib (n = 62) to understand associations with clinical variables. A complete response to sunitinib could be achieved irrespective of prognostic group, metastasis site or histology type. Introduction: The long-term clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) and a complete response (CR) to the tyrosine kinase inhibitor (TKI) sunitinib are poorly known. The characteristics of these patients could reveal previously undetected associations with clinical variables. Patients and Methods: This observational, retrospective study (ATILA) used data from a registry of patients with mRCC who had received first-line sunitinib and had achieved CR from 2007 to 2018 in Spain. Results: Sixty-two patients with CR were included; 48 patients (77.4%) received sunitinib in monotherapy and 14 (22.6%) combined with or followed by local treatment. Median age was 58.5 years (range, 32-81). Most patients (79.0%) had clear cell histology and had undergone previous nephrectomy (90.3%). The majority (70.2%) had an intermediate IMDC prognosis, 23% favorable and 7.0% poor. The median time on treatment with sunitinib was 28.2 months (IQR, 16.7-41.0) and the median time to CR was 10.9 months (IQR, 7.2-19.3). After a median follow-up of 8 years (range, 3-13 years), the median PFS was not reached. The overall median duration of complete response was 64.1 months (IQR, 32.2-99.4). The tolerance and safety profile of sunitinib was consistent with previous reports. Conclusion: Durable CR to sunitinib was observed in patients regardless the prognosis group, metastasis site or histology type, with 75% of patients remaining in CR after 10 years. Clinicaltrials.gov: NCT03916458. [ABSTRACT FROM AUTHOR]

المؤلفون: Molina-Cerrillo, Javier, Martínez-Sáez, Olga, Alonso-Gordoa, Teresa, Tirado-Zambrano, Pedro, Delgado-Vargas, Beatriz, Earl, Julie, Grande, Enrique

المصدر: Clinical Genitourinary Cancer; December 2015, Vol. 13 Issue: 6 p493-498, 6p

مستخلص: Bladder cancer remains a frequent cancer worldwide, and most tumors are diagnosed at localized stages. Urothelial carcinoma (UC) accounts for 90% of bladder cancer cases. Sarcomatoid carcinoma (SaC) of the bladder is a rare variant (0.5% of total bladder cancers) characterized by 2 components based on histology; the epithelial and mesenchymal phenotypes, which can be easily differentiated by immunohistochemistry. SaC has similar epidemiologic features to UC but different behavior, aggressiveness, and prognosis. In this review, we summarize the main differences between UC bladder cancers and SaC subtypes. The therapeutic strategies used in SaC today do not differ much from those used for the urothelial variant. However, there is still no standard treatment—the result of a lack of clinical trials for the sarcomatoid variant. Further multicenter comparative studies are needed to devise a better treatment strategy for patients with this rare histologic tumor subtype.